Awiqli

Insulin Icodec, the active ingredient in Awiqli, is a long-acting insulin analog presented as a 700 units/mL solution for subcutaneous use. It is used to manage blood glucose levels in adults with type 1 or type 2 diabetes mellitus. GNH USA supplies Awiqli as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Awiqli is designed to provide a steady release of insulin over an extended period, making it a convenient option for patients requiring long-term diabetes management.

Awiqli is a long-acting insulin analog used to manage blood glucose levels in adults with diabetes mellitus. It is indicated for the following conditions:

- Type 1 Diabetes Mellitus: Helps manage blood glucose levels in combination with rapid-acting insulin. - Type 2 Diabetes Mellitus: Can be used alone or in combination with other antidiabetic medications to control blood glucose levels. - Long-term Glucose Control: Provides a steady release of insulin to maintain stable blood glucose levels throughout the week.

Awiqli, like all medications, can cause side effects. Common side effects include:

Common Side Effects: - Hypoglycemia (low blood sugar): Can occur if the dose is too high or if meals are skipped. - Injection site reactions: May include redness, swelling, or itching at the injection site. - Weight gain: Can occur due to the anabolic effects of insulin. - Peripheral edema: Swelling in the extremities may occur due to fluid retention.

Serious or Rare Side Effects: - Severe hypoglycemia: Can lead to loss of consciousness or seizures if not managed promptly. - Hypersensitivity reactions: Allergic reactions to the medication can occur, ranging from mild to severe. - Lipodystrophy: Changes in fat distribution at the injection sites may occur with long-term use. - Cardiovascular events: Increased risk of cardiovascular events in patients with a history of heart disease.

Awiqli should be used with caution and under the supervision of a healthcare professional. Important precautions include:

- Dose Adjustment: Regular monitoring of blood glucose levels is essential to adjust the dose as needed. - Hypoglycemia Management: Patients should be educated on recognizing and managing symptoms of hypoglycemia. - Injection Technique: Proper injection technique should be followed to minimize the risk of injection site reactions. - Drug Interactions: Inform healthcare providers about all medications being taken to avoid potential interactions. - Storage: Store unopened Awiqli in the refrigerator between 2°C and 8°C. Once opened, it can be stored at room temperature up to 30°C for up to 12 weeks. Do not freeze or expose to direct sunlight.

Awiqli can interact with other medications, which may affect its efficacy or increase the risk of side effects. Major and moderate interactions include:

Major Interactions (Avoid): - Oral hypoglycemic agents: Concomitant use can increase the risk of severe hypoglycemia. - Beta-blockers: Can mask the symptoms of hypoglycemia and delay recovery. - Monoamine oxidase inhibitors (MAOIs): Can enhance the hypoglycemic effect of insulin.

Moderate Interactions (Monitor Closely): - Corticosteroids: Can reduce the blood glucose-lowering effect of insulin. - Diuretics: May increase the risk of hypoglycemia. - Antipsychotics: Can affect blood glucose levels and require close monitoring.